A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape

被引:7
|
作者
Xie, Peiling [1 ]
An, Rui [2 ]
Yu, Shibo [1 ]
He, Jianjun [1 ]
Zhang, Huimin [1 ]
机构
[1] Xi An Jiao Tong Univ, Dept Breast Surg, Affiliated Hosp 1, 277 West Yanta Rd, Xian 710061, Peoples R China
[2] Xi An Jiao Tong Univ, Dept Hepatol Surg, Affiliated Hosp 1, 277 West Yanta Rd, Xian 710061, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; ER+/PR-/HER2-; Immune classification; Multi-omics; PROGESTERONE-RECEPTOR EXPRESSION; PREDICTIVE-VALUE; PD-1; BLOCKADE; CROSS-TALK; ESTROGEN; TAMOXIFEN; GROWTH; TUMORS; IMMUNOTHERAPY; MECHANISMS;
D O I
10.1186/s12967-021-03076-x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: The diversity and plasticity behind ER+/PR-/HER2- breast cancer have not been widely explored. It is essential to identify heterogeneous microenvironment phenotypes and investigate specific genomic events driving the formation of these phenotypes. Methods: Based on the immune-related gene expression profiles of 411 ER+/PR-/HER2- breast cancers in the METABRIC cohort, we used consensus clustering to identify heterogeneous immune subtypes and assessed their reproducibility in an independent meta-cohort including 135 patients collected from GEO database. We further analyzed the differences of cellular and molecular characteristics, and potential immune escape mechanism among immune subtypes. In addition, we constructed a transcriptional trajectory to visualize the distribution of individual patient. Results: Our analysis identified and validated five reproducible immune subtypes with distinct cellular and molecular characteristics, potential immune escape mechanisms, genomic drivers, as well as clinical outcomes. An immune-cold subtype, with the least amount of lymphocyte infiltration, had a poorer prognosis. By contrast, an immune-hot subtype, which demonstrated the highest infiltration of CD8+ T cells, DCs and NK cells, and elevated IFN-gamma response, had a comparatively favorable prognosis. Other subtypes showed more diverse gene expression and immune infiltration patterns with distinct clinical outcomes. Finally, our analysis revealed a complex immune landscape consisting of both discrete cluster and continuous spectrum. Conclusion: Overall, this study revealed five heterogeneous immune subtypes among ER+/PR-/HER2- breast cancer, also provided important implications for clinical translations.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
    Peiling Xie
    Rui An
    Shibo Yu
    Jianjun He
    Huimin Zhang
    Journal of Translational Medicine, 19
  • [2] Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
    Taobo Hu
    Yan Chen
    Yiqiang Liu
    Danhua Zhang
    Jiankang Pan
    Mengping Long
    BMC Medical Research Methodology, 21
  • [3] Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
    Hu, Taobo
    Chen, Yan
    Liu, Yiqiang
    Zhang, Danhua
    Pan, Jiankang
    Long, Mengping
    BMC MEDICAL RESEARCH METHODOLOGY, 2021, 21 (01)
  • [4] Immune subtyping of ER-positive, PR-negative and HER2-negative breast cancers by immunohistochemistry: Molecular basis and clinical relevance.
    Zhang, Huimin
    Zhao, Yuting
    Xie, Peiling
    Chen, Heyan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer
    Hageman, Elizabeth
    Lussier, Mia E.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (08) : 849 - 856
  • [6] Genomic characterization of the HER2-enriched intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer
    Lennart Hohmann
    Kristin Sigurjonsdottir
    Ana Bosch Campos
    Deborah F. Nacer
    Srinivas Veerla
    Frida Rosengren
    Poojaswini Thimmaraya Reddy
    Jari Häkkinen
    Nicklas Nordborg
    Johan Vallon-Christersson
    Yasin Memari
    Daniella Black
    Ramsay Bowden
    Helen R. Davies
    Åke Borg
    Serena Nik-Zainal
    Johan Staaf
    Nature Communications, 16 (1)
  • [7] Elacestrant in advanced ER-positive, HER2-negative breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (01) : 17 - 17
  • [8] Novel Endocrine Therapy Agents in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    Rugo, Hope S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (03) : 125 - 127
  • [9] Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
    Christopher D. Hart
    Ilenia Migliaccio
    Luca Malorni
    Cristina Guarducci
    Laura Biganzoli
    Angelo Di Leo
    Nature Reviews Clinical Oncology, 2015, 12 : 541 - 552
  • [10] Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer
    Abraham, Jame
    Mechcatie, Elizabeth
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (03): : 83 - 86